Drug-eluting stent pricing
This article was originally published in The Gray Sheet
Executive Summary
J&J/Cordis's apparent European drug-eluting stent bundling scheme will ultimately impair the firm's ability to compete once competitors launch similar devices in Europe, according to Boston Scientific. "J&J's most recent pricing list, which offers a range of prices down to $1,500, is very explicitly not a geographically-based price list, but a volume-based price list," Boston Scientific Cardiovascular President Paul LaViolette tells investors April 16. "I think the reception in the market place to that pricing scheme is generally negative, so it will be less an issue of us fending off J&J from bundling and more of an issue of the customers battling J&J." Cordis launched the Cypher sirolimus-eluting stent April 12, following CE mark approval. Boston Scientific expects a CE mark for its NIRx in approximately six months...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.